Evandro Dantas Bezerra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Evandro Dantas Bezerra has a total of 251 co-authors. Here are the top co-authors by number of shared publications:
- Claudia Manriquez Roman
T Cell Engineering, Mayo Clinic, Rochester, MN
23 shared publications - Elizabeth L. Siegler
T Cell Engineering, Mayo Clinic, Rochester, Minnesota
23 shared publications - Ismail Can
Division of Hematology, Mayo Clinic, Rochester, USA
23 shared publications - Lionel Aurelien Kankeu Fonkoua
Department of Oncology, Mayo Clinic , Rochester, MN 55905
23 shared publications - Neil E. Kay
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN
23 shared publications - R. Leo Sakemura
T Cell Engineering, Mayo Clinic, Rochester, MN
23 shared publications
Latest Publications
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
Supplementary Figure 2. Trispecific CAR T Cell Persistence by gag gene PCR (single dose infusion versus split dose infusion).
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
Supplementary Figure 2. Trispecific CAR T Cell Persistence by gag gene PCR (single dose infusion versus split dose infusion).
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
Supplementary Figure 4. Immunophenotypic and functional characteristics CD8+ CAR + T cells and CD4+ CAR + T cells in post-CAR T infusion PBMCs at Day 7.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
Supplementary Figure 4. Immunophenotypic and functional characteristics CD8+ CAR + T cells and CD4+ CAR + T cells in post-CAR T infusion PBMCs at Day 7.
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
Supplementary Figure 1. Trial Schema.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
Supplementary Figure 1. Trial Schema.
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
Supplementary Table 2. Toxicity and other clinical outcomes.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
Supplementary Table 2. Toxicity and other clinical outcomes.
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
Supplementary Figure 6. Trispecific CAR + T cell Gating Strategy for spectral flow cytometry.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
Supplementary Figure 6. Trispecific CAR + T cell Gating Strategy for spectral flow cytometry.
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
Supplementary Figure 3. Statistical Analysis (Area Under the Curve) Trispecific CAR T Cell Persistence by PCR Data.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
Supplementary Figure 3. Statistical Analysis (Area Under the Curve) Trispecific CAR T Cell Persistence by PCR Data.
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
Supplementary Figure 5: Immunophenotypic and functional characteristics CD8+ CAR + T cells and CD4+ CAR + T cells in Post-CAR T PBMCs at Day 14.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
Supplementary Figure 5: Immunophenotypic and functional characteristics CD8+ CAR + T cells and CD4+ CAR + T cells in Post-CAR T PBMCs at Day 14.
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
Supplementary Table 1. Representativeness of Study Participants.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
Supplementary Table 1. Representativeness of Study Participants.
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
Supplementary Table 3. 40 color spectral flow cytometry CAR T cell immunophenotyping panel.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
Supplementary Table 3. 40 color spectral flow cytometry CAR T cell immunophenotyping panel.